Intra-Cellular Therapies Inc. Stock News

Investing in biotech stocks is not for the faint of heart. The sector is prone to wild swings in stock prices, offering a distinctive blend of high risk and high reward.

Intra-Cellular (ITCI) jumps 23% after achieving key goals in the late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.

Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increas

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv

Intra-Cellular (ITCI) reports mixed fourth-quarter 2023 results despite Caplyta sales rising year over year on the back of increasing prescription trends.

Now that the FED is looking to lower interest rates this year, cheaper money and more accessible financing will let investors venture into riskier places in the economy and the stock market. While not

Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.

Intra-Cellular's share price has increased by 450% over a five-year period and over 50% in the past year. The company's success is attributed to its approved drug, Caplyta, which has driven significan

NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv

The biotech sector is finishing 2023 on a high after a difficult couple of years, buoyed by Big Pharma M&A activity. The SPDR® S&P Biotech ETF has been soaring as a result of the M&A spree. Despite a

Does Intra-Cellular Therapies (ITCI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.

Intra-Cellular Therapies, Inc. is a mid-cap biopharmaceutical company focused on developing treatments for neuropsychiatric and neurological disorders. The company's commercial asset, Caplyta, has ach

Intra-Cellular Therapies shows strong financial growth, driven by Caplyta sales, with improved operational efficiency and reduced net losses. Caplyta's success in schizophrenia and bipolar depression,

Intra-Cellular (ITCI) third-quarter 2023 earnings and revenues beat estimates. Caplyta sales continue to drive growth.